Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Closed |
Open Access Green as soon as Postprint is submitted to ZB.
Giving T-cell bispecifics a helping hand.
Blood 143, 2115-2116 (2024)
In this issue of Blood, Sam et al demonstrate the translational potential of CD19-targeted CD28-mediated costimulation to ameliorate the therapeutic potential of the anti-CD19-anti-CD3 T-cell bispecific engager glofitamab in preclinical models, buttressing the rationale for an ongoing phase 1 clinicalstudy.(1)
Altmetric
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Editorial
Language
english
Publication Year
2024
HGF-reported in Year
2024
ISSN (print) / ISBN
0006-4971
e-ISSN
1528-0020
Journal
Blood
Quellenangaben
Volume: 143,
Issue: 21,
Pages: 2115-2116
Publisher
American Society of Hematology
Publishing Place
2021 L St Nw, Suite 900, Washington, Dc 20036 Usa
Reviewing status
Peer reviewed
Institute(s)
Unit for Clinical Pharmacology (KKG-EKLiP)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-522100-001
WOS ID
001245908300001
Scopus ID
85192805765
PubMed ID
38780922
Erfassungsdatum
2024-05-22